Research on cancer has been going on for years, and as of late, the industry is making significant successful breakthroughs. Antibody Breakthrough Therapies is the new game changer that is likely to replace the older methods like Chemotherapy. These new breakthrough therapies have been considered to be more superior to traditional treatments. Clay Siegall is at the forefront of coming up with these new and advanced treatment options for battling cancer. Together with his team at Seattle Genetics, they understand every cancer differs from the other, and so deserves a treatment option specifically tailored to it.
Dr. Siegall’s Role at Seattle Genetics
As CEO, Siegall has led the Seattle Genetics to its current leading position in the development of antibody-drug conjugates (ADCs) as well as in getting the 2011 FDA authorization of its ADC product, ADCETRIS. Collaboration with the Takeda Pharmaceutical Company has led to ADCETRIS to become a global brand that has been approved by over sixty countries. The firm is also improving a different channel of proprietary ADCs.
Under the stewardship of Dr. Siegall, the firm has got into various strategic licenses for the ADC technology with firms that include GlaxoSmithKline, Pfizer, AbbVie, and Genentech. The collaboration has been able to generate over $325 million. Across the internal and collaborator programs, over twenty ADCs exist in clinical development using technology obtained from Seattle Genetics. Siegall has also led capital-raising activities of the firm, and he has been able to secure over $1.2 billion through private and public financings. Financing also included the company’s IPO in 2001.
About Clay Siegall
Clay Siegall, Ph.D., is a scientist by training. He has focused more on targeted cancer therapies, which is what led him to co-found the Seattle Genetics in 1998. The institute was established on a foundation of rigorous research, scientific innovation and drug development in addition to a desire for helping patients.
Before co-founding Seattle Genetics, Siegall worked with Bristol-Myers Squip Pharmaceutical Research Institute, National Cancer Institute, and the National Institute of Health. He serves on the Board of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. Dr. Siegall has been a recipient of various awards, including Maryland Alumnus of the Year, 2013; and the Pacific Northwest Ernst and Young Entrepreneur of the Year, 2012. He has authored over seventy publications and has fifteen patents.